HomePress ReleaseSeraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit.
Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes.